Ixaltis Sa

ixaltis is a specialty pharmaceutical company developing proprietary therapeutics to treat genitourinary (gu) disorders with unsatisfied medical need. the company was born from the combined expertise of leading scientists specialised in this field and of experienced managers. ixaltis has already obtained an exclusive worldwide license for three molecules from sanofi (ixa-001, ixa-002 and ixa-003). ixaltis has established a proprietary position covering ixa-001 for use in urogenital and other disorders based on its specific mechanism of action. « our company has the objective of becoming a leading developer of innovative pharmaceutical products for treating disorders of the urogenital tract, bringing to the clinic solutions for diseases that affect many people and for which there are few or no satisfactory treatments ».